molecular
techniqu
revolution
detect
identifi
cation
microorgan
realtim
pcr
allow
rapid
accur
detect
mrsa
vre
group
b
streptococcu
identifi
cation
diffi
cult
slowgrow
organ
expedit
sequencebas
method
rrna
gene
sequenc
rapid
identif
organ
detect
resist
marker
directli
posit
blood
cultur
bottl
becom
realiti
final
transform
take
place
introduct
malditof
clinic
laboratori
promis
improv
accuraci
speed
bacteri
fungal
identifi
cation
day
advantag
methodolog
associ
clinic
applic
along
inher
pitfal
problem
elucid
chapter
gener
popul
age
incid
chronic
condit
rise
preval
antimicrobi
resist
increas
emerg
pathogen
aris
laboratori
diagnosi
infecti
diseas
evolv
becom
complex
complex
diagnost
microbiolog
increas
method
employ
detect
infecti
agent
implement
molecular
technolog
clinic
microbiolog
laboratori
case
augment
tradit
method
cultur
serolog
circumst
complet
replac
tradit
method
routin
bacteriolog
ie
blood
cultur
urin
cultur
respiratori
cultur
cultur
remain
gold
standard
primarili
base
lower
cost
potenti
complex
natur
infect
howev
situat
low
quantiti
pathogen
may
present
patient
may
receiv
antibiot
prior
specimen
collect
etiolog
agent
may
requir
unusu
cultur
condit
rapid
turnaround
time
need
molecular
test
approach
particularli
benefi
cial
current
optim
use
molecular
techniqu
microbiolog
resid
specimen
limit
number
pathogen
organ
sought
ie
detect
methicillinresist
staphylococcu
aureu
nare
vancomycinresist
enterococcu
rectal
swab
case
enhanc
sensit
decreas
turnaround
time
andor
patient
impact
molecular
method
outweigh
increas
cost
laboratori
ie
molecular
identifi
cation
organ
directli
posit
blood
cultur
particularli
excit
transit
clinic
microbiolog
use
mass
spectrometri
ms
identifi
cation
wide
spectrum
bacteri
fungal
organ
well
detect
antimicrobi
resist
chapter
discuss
common
molecular
method
applic
clinic
bacteriolog
laboratori
includ
associ
advantag
disadvantag
molecular
method
use
identifi
cation
bacteri
organ
cultur
patient
specimen
includ
direct
probe
hybrid
sequenc
direct
probe
hybrid
use
cultur
confi
rmation
well
direct
detect
organ
clinic
materi
nucleic
acid
probe
peptid
nucleic
acid
pna
probe
commerci
avail
probe
singlestrand
oligonucleotid
vari
size
base
pair
bp
kilobas
gener
less
bp
probe
specifi
citi
defi
ned
nucleic
acid
sequenc
probe
bacteri
identifi
cation
use
probe
rrna
rrna
commonli
use
due
rel
high
copi
number
rrna
bacteria
increas
sensit
direct
detect
rrna
sequenc
contain
conserv
region
addit
hypervari
region
allow
level
identifi
cation
vari
depend
probe
sequenc
commerci
avail
probe
cultur
confi
rmation
includ
group
b
streptococcu
listeria
monocytogen
neisseria
gonorrhoea
staphylococcu
aureu
streptococcu
pneumonia
sever
mycobacteria
includ
tuberculosi
holog
san
diego
ca
addit
probe
direct
detect
group
streptococcu
throat
swab
avail
holog
although
expens
convent
cultur
identifi
cation
method
probebas
detect
identifi
cation
method
moder
increas
sensit
specifi
citi
decreas
turnaround
time
howev
falseneg
falseposit
result
may
occur
bacteri
strain
may
possess
polymorph
prevent
probe
hybrid
differ
strain
may
contain
similar
sequenc
result
crossreact
addit
disadvantag
probe
hybrid
method
limit
number
commerci
probe
inabl
probe
clinic
specimen
directli
situ
hybrid
ish
allow
detect
nucleic
acid
sequenc
cell
tissu
fi
xed
glass
slide
probe
dna
rna
pna
typic
short
bp
allow
easier
penetr
access
target
sequenc
colorimetr
fl
uoresc
ish
fish
probe
use
histopatholog
clinic
microbiolog
advantag
ish
histopatholog
abil
evalu
host
tissu
respons
identifi
cation
specifi
c
cell
contain
infecti
agent
addit
noncultur
diffi
cult
cultur
organ
detect
ish
ie
tropheryma
whipplei
whippl
diseas
disadvantag
includ
autofl
uoresc
microorgan
includ
pseudomona
legionella
mani
yeast
mold
specifi
citi
reliabl
certain
probe
sequenc
insuffi
cient
probe
penetr
sampl
materi
secondari
structur
target
sequenc
low
target
content
photobleach
clinic
microbiolog
direct
identifi
cation
microbi
organ
patient
sampl
cultur
often
determin
use
commerci
pnafish
probe
advandx
woburn
pna
probe
neutral
peptidelik
backbon
oppos
neg
charg
sugarphosph
backbon
dna
probe
howev
like
dna
probe
pna
probe
hybrid
dna
rna
sequencespecifi
c
manner
fl
uoresc
label
eas
detect
report
advantag
pna
probe
includ
stronger
faster
hybrid
discrimin
one
bp
differ
resist
nucleas
proteas
surviv
stringent
condit
eg
high
temperatur
allow
access
region
secondari
structur
increas
hydrophob
allow
penetr
cell
membran
ish
commerci
pna
probe
includ
mani
multilabel
probe
kit
discrimin
morpholog
similar
organ
includ
staphylococcu
aureu
coagulaseneg
staphi
lococcu
enterococcu
faecali
enterococci
escherichia
coli
pseudomona
aeruginosa
gramneg
rod
e
coli
p
aeruginosa
klebsiella
pneumonia
yeast
c
albican
parapsilosi
c
tropicali
c
glabrata
krusei
group
b
streptococcu
advandx
inc
woburn
pnafish
probe
use
clinic
laboratori
identifi
cation
organ
posit
blood
cultur
bottl
less
h
signifi
cant
posit
impact
patient
care
institut
cost
save
mani
larger
laboratori
sequenc
use
rapidli
accur
identifi
organ
sequenc
rapid
convent
method
initi
growth
isol
still
requir
prior
sequenc
ideal
applic
sequenc
organ
identifi
cation
includ
mycobacterium
spp
aerob
actinomycet
includ
nocardia
spp
select
anaerob
gramposit
bacteria
organ
typic
slowgrow
diffi
cult
identifi
routin
method
sequenc
also
use
identifi
organ
cultur
inher
diffi
cult
grow
result
antibiot
therapi
situat
sequenc
would
need
perform
directli
clinic
specimen
practic
must
use
caution
specimen
steril
site
substanti
bodi
evid
exist
direct
sequenc
explant
heart
valv
identifi
cation
organ
caus
endocard
mani
bacteri
genom
region
use
sequencebas
identifi
cation
clinic
laboratori
rrna
gene
common
target
rrna
gene
encod
highli
conserv
rrna
associ
small
subunit
ribosom
often
use
taxonom
purpos
speci
identifi
cation
rrna
highli
conserv
among
bacteria
nucleotid
variat
uniqu
speci
concentr
specifi
c
region
entir
gene
bp
includ
conserv
variabl
region
discriminatori
sequenc
gener
obtain
use
bp
univers
primer
complementari
conserv
region
either
side
variabl
region
permit
amplifi
cation
bacteri
speci
result
amplicon
contain
uniqu
sequenc
identifi
cation
commerci
research
use
kit
avail
sequenc
rrna
microseq
appli
biosystem
thermo
fisher
scientifi
c
waltham
mani
clinic
laboratori
use
laboratorydevelop
protocol
notabl
organ
ident
rdna
sequenc
eg
chelona
abscessu
pneumonia
miti
howev
ident
organ
rdna
sequenc
differenti
sequenc
gene
intern
transcrib
space
region
rpob
seca
sequenc
result
robust
convent
cultur
method
less
subject
comprehens
accur
databas
use
sequenc
comparison
analysi
sequenc
data
involv
evalu
qualiti
sequenc
obtain
subsequ
comparison
sequenc
known
sequenc
public
andor
commerci
databas
ncbi
genbank
microseq
integr
databas
network
system
smartgen
raleigh
nc
ripseq
isentio
palo
alto
ca
isol
grow
cultur
entir
procedur
done
work
day
beyond
rel
long
time
result
compar
mass
spectrometri
limit
qualiti
public
databas
expens
access
curat
databas
similar
rrna
sequenc
organ
major
advanc
bacteri
identifi
cation
routin
use
mass
spectrometri
ms
clinic
microbiolog
laboratori
tradit
bacteri
identifi
cation
achiev
perform
number
biochem
reaction
identifi
uniqu
combin
phenotyp
properti
specifi
c
particular
microorgan
origin
perform
individu
phenotyp
test
streamlin
perform
autom
instrument
although
autom
system
reduc
time
identifi
cation
rel
tradit
method
still
room
improv
use
ms
identifi
organ
fi
rst
describ
advent
use
matrix
assist
ms
reliabl
reproduc
suffi
cient
clinic
applic
type
ms
commonli
use
clinic
microbiolog
atrix
ssist
l
aser
esorpt
oniz
ime
f
f
light
malditof
ms
illustr
fig
core
malditof
ms
bacteri
identifi
cation
differ
dna
lead
organ
b
fragment
protein
produc
organismspecifi
c
spectra
compar
refer
databas
spectra
organ
identifi
cation
differ
protein
composit
organ
differ
protein
composit
resolv
malditof
ms
technolog
work
use
laser
creat
cloud
ion
current
appli
releas
fl
ight
chamber
ion
gener
bacteri
isol
smear
onto
target
slide
overlaid
matrix
solut
typic
acid
matrix
solut
critic
even
distribut
laser
energi
gener
primarili
singli
charg
ion
reproduc
result
process
use
smear
bacteri
isol
often
refer
whole
cell
intact
cell
ms
wcm
icm
ion
travel
fl
ight
chamber
separ
accord
size
charg
smallest
highli
charg
particl
move
fastest
chamber
ion
strike
detector
end
chamber
spectrum
gener
provid
rel
quantiti
ion
particular
masscharg
ratio
spectra
algorithm
compar
refer
databas
ident
confi
denc
valu
assign
much
like
rrna
gene
sequenc
strength
applic
reli
robust
refer
databas
comparison
sever
studi
shown
identifi
cation
rate
signifi
cantli
increas
databas
augment
also
much
qualiti
sequenc
read
necessari
identifi
cation
high
qualiti
spectra
must
good
refer
match
identifi
cation
ideal
spectra
identifi
cation
typic
consist
protein
kda
rang
rich
ribosom
cytoplasm
protein
obtain
qualiti
spectra
use
wcm
diffi
cult
organ
mycobacteria
fi
lament
fungi
yeast
due
rigid
cell
wall
therefor
organ
must
undergo
addit
extract
step
make
intern
cellular
protein
access
ioniz
basic
extract
step
appli
formic
acid
solut
smear
spot
allow
dri
ad
matrix
solut
higher
order
bacteria
mycobacteria
nocardia
spp
fi
lament
fungi
requir
rigor
extract
typic
involv
bead
beat
formic
acid
acetonitril
treatment
gener
malditof
ms
perform
well
typic
identifi
routin
organ
correct
speci
two
malditof
ms
platform
current
use
clinic
microbiolog
laboratori
maldi
biotyp
bruker
daltron
billerica
vitek
ms
biomerieux
durham
nc
offer
fdaclear
databas
addit
develop
malditof
ms
clinic
microbiolog
laboratori
includ
detect
antimicrobi
resist
direct
pathogen
detect
blood
cultur
see
anoth
emerg
technolog
identifi
cation
microorgan
use
pcr
electrosprayion
mass
spectrometri
esim
methodolog
use
conserv
primer
gener
pcr
amplicon
directli
specimen
sourc
well
ms
gener
approxim
base
content
amplicon
inform
uniqu
enough
develop
spectral
signatur
differ
organ
spectra
compar
databas
provid
like
identifi
cation
base
primer
set
use
well
rel
abund
organ
identifi
ed
pcr
esim
sever
advantag
direct
detect
wide
varieti
potenti
pathogen
virus
bacteria
fungi
specimen
rapid
costeffect
test
compar
sequenc
technolog
nextgener
sequenc
provid
inform
outsid
constraint
arraybas
technolog
abl
queri
limit
number
predefi
ned
organ
fact
technolog
use
pathogen
discoveri
new
pathogen
identifi
ed
group
similar
known
organ
done
success
sudden
acut
respiratori
syndrom
sar
pandem
still
new
technolog
work
remain
done
optim
process
routin
clinic
use
includ
optim
extract
method
well
develop
addit
primer
set
increas
emphasi
faster
turnaround
time
result
combin
avail
target
therapeut
creat
nich
rapid
molecular
detect
resist
determin
clinic
microbiolog
laboratori
antimicrobi
resist
detect
probe
hybrid
nucleic
acid
amplifi
cation
naa
technolog
pcr
sequenc
howev
use
molecular
method
detect
microbi
resist
without
limit
multifactori
resist
mechan
polyclon
polymicrobi
infect
phenotyp
synerg
unknown
genotypephenotyp
relationship
prevent
accur
determin
resist
use
molecular
method
establish
applic
molecular
bacteri
resist
test
detect
methicillinresist
staphylococcu
aureu
mrsa
resist
methicillin
staphylococci
almost
exclus
caus
singl
mechan
alter
penicillin
bind
protein
conform
chang
mediat
welldefi
ned
genet
compon
meca
gene
alter
lower
affi
niti
methicillin
penicillinasest
resist
confer
tradit
detect
method
includ
chromogen
agar
oxacillin
screen
agar
tradit
disk
diffus
cefoxitin
minimum
inhibitori
concentr
test
oxacillin
method
requir
h
incub
decreas
time
differenti
methicillinsuscept
staphylococcu
aureu
mssa
mrsa
use
either
proteinbas
method
latex
oxoid
cambridg
uk
molecular
method
detect
meca
gene
see
associ
improv
patient
outcom
institut
cost
save
first
detect
nearli
year
introduct
vancomycin
vancomycinresist
enterococci
vre
develop
part
due
increas
use
vancomycin
clostridium
diffi
cile
coliti
mrsa
infect
vancomycin
act
block
transglycosyl
transpeptid
step
cell
wall
biosynthesi
resist
phenotyp
base
lower
affi
niti
vancomycin
target
peptidoglycan
precursor
encod
van
gene
highlevel
resist
mic
encod
vana
vanb
typic
found
transposon
chromosom
associ
vand
gener
found
enterococcu
faecium
enterococcu
faecali
also
chromosom
encod
vanc
gene
enterococcu
gallinarum
enterococcu
casselifl
avu
enterococcu
fl
avescen
associ
lowlevel
resist
mic
vana
vanb
tend
resid
mobil
element
confer
highlevel
resist
detect
enterococci
contain
resist
determin
critic
effect
infect
control
measur
although
numer
laboratorydevelop
naa
assay
commerci
analyt
specifi
c
reagent
asr
avail
assay
molecular
detect
vre
rectal
site
clear
us
food
drug
administr
fda
xpert
vana
test
cepheid
sunnyval
ca
bd
geneohm
vanr
becton
dickinson
spark
md
imdx
vanr
intellig
medic
devic
beverli
although
vre
usa
europ
commonli
contain
vana
vanb
also
consid
due
lower
signifi
cant
preval
main
advantag
molecular
detect
vre
increas
sensit
increas
specifi
citi
exclus
vanc
mediat
resist
decreas
timetoresult
although
resist
antituberculosi
drug
new
phenomenon
new
method
develop
identifi
resist
strain
due
slow
growth
tuberculosi
tb
molecular
techniqu
well
suit
detect
tb
directli
patient
specimen
also
screen
resist
see
chap
sever
test
kit
cemark
clinic
use
europ
includ
genotyp
mtbdr
system
hain
lifesci
germani
innogenet
innolipa
riftb
gent
belgium
xpert
mtbrif
cartridg
cepheid
genexpert
platform
latter
also
receiv
fda
clearanc
system
detect
rifampin
resist
common
resist
found
among
fi
rstline
tb
drug
addit
rifampin
resist
marker
multidrugresist
mdr
tb
geograph
region
endem
mdrtb
rifampin
resist
determin
analyz
rpob
gene
specifi
c
mutat
bp
rifampin
resist
determin
region
use
hybrid
probe
genotyp
mtbdr
system
also
determin
isoniazid
resist
screen
katg
inha
gene
expand
genotyp
mtbdrsl
panel
add
detect
resist
fl
uoroquinolon
aminoglycosid
ethambutol
addit
inform
mycobacteri
detect
resist
found
chap
much
like
revolutionari
impact
bacteri
identifi
cation
ms
like
impact
resist
test
preliminari
studi
demonstr
rapid
identifi
cation
mrsa
extend
spectrum
beta
lactamas
esbl
organ
carbapenemaseproduc
organ
malditof
ms
resist
organ
identifi
ed
two
way
use
ms
similar
genet
approach
resist
organ
identifi
ed
presenc
absenc
characterist
mass
peak
approach
wide
use
identifi
cation
mrsa
ms
though
confl
ict
report
effect
approach
identifi
resist
organ
use
ms
appli
phenotyp
approach
measur
substrat
modifi
cation
exampl
determin
presenc
microbi
carbapenemas
carbapenem
test
organ
coincub
follow
ms
detect
nativ
carbapenem
drug
peak
andor
peak
hydrolyz
product
supernat
although
approach
detect
resist
mechan
modifi
substrat
distinct
advantag
look
phenotyp
instead
particular
resist
determin
especi
use
case
esbl
carbapenemas
mani
genet
determin
caus
phenotyp
screen
patient
mrsa
nasal
colon
central
strategi
prevent
spread
organ
health
care
set
refer
method
use
accur
detect
resist
due
alter
aureu
naa
detect
meca
gene
convent
realtim
pcr
use
detect
meca
bacteri
isol
directli
patient
specimen
howev
direct
specimen
test
limit
often
includ
lower
posit
predict
valu
convent
method
base
possibl
codetect
mssa
methicillinresist
coagulaseneg
staphylococci
manufactur
circumv
problem
detect
scc
mecorf
junction
aureu
genom
howev
strain
contain
scc
mec
cassett
nonfunct
delet
meca
socal
meca
dropout
fals
posit
addit
mrsa
strain
carri
mecc
meca
homologu
fals
neg
assay
though
preval
strain
still
low
sever
fdaclear
molecular
assay
avail
detect
mrsa
without
mssa
detect
nasal
swab
clinic
specimen
posit
blood
cultur
swab
obtain
skin
soft
tissu
infect
tabl
naa
detect
mrsa
least
equal
sensit
culturebas
method
advantag
offer
faster
turnaround
time
combin
appropri
infect
control
intervent
may
signifi
cantli
decreas
hospit
cost
decreas
number
healthcareassoci
mrsa
infect
although
incid
group
b
streptococcu
gb
neonat
diseas
declin
sinc
due
enhanc
prevent
effort
still
lead
infecti
caus
morbid
mortal
neonat
usa
center
diseas
control
prevent
cdc
american
colleg
obstetrician
gynecologist
american
academi
pediatr
fi
rst
publish
guidelin
perform
vaginalrect
screen
pregnant
women
week
gestat
women
colon
given
intrapartum
prophylact
treatment
thu
accur
gb
result
critic
ensur
appropri
antibiot
administr
addit
woman
gb
colon
statu
known
due
lack
prenat
care
prematur
deliveri
receiv
prophylact
antibiot
base
risk
assess
specifi
calli
gestat
less
week
membran
ruptur
h
prior
deliveri
fever
greater
sinc
antibiot
administr
without
risk
mother
newborn
intrapartum
rapid
molecular
test
gb
colon
benefi
cial
fi
rst
molecular
techniqu
use
routin
gb
screen
direct
probe
hybrid
either
coloni
swabinocul
lim
broth
although
provid
advantag
decreas
turnaround
time
reduc
technologist
time
costeffect
routin
antepartum
screen
develop
molecular
technolog
gb
detect
result
seven
fdaclear
molecular
test
tabl
numer
laboratorydevelop
test
ldt
notabl
bd
geneohm
strepb
test
bd
geneohm
scienc
san
diego
ca
cepheid
smart
gb
xpert
gb
offer
detect
gb
directli
rectovagin
swab
antepartum
intrapartum
detect
gb
colon
fdaclear
xpert
gb
perform
genexpert
cepheid
moderatecomplex
test
selfcontain
extract
result
technolog
make
random
access
test
intrapartum
screen
feasibl
given
approxim
women
neg
cultur
week
gestat
gb
posit
time
deliveri
intrapartum
test
accur
test
colon
time
deliveri
intrapartum
screen
test
one
institut
xpert
gb
sensit
specifi
citi
wherea
antenat
cultur
sensit
specifi
c
intrapartum
cultur
use
gold
standard
multicent
studi
idistrepb
assay
bd
geneohm
intrapartum
cultur
gold
standard
molecular
detect
time
labor
sensit
specifi
c
rel
either
sensit
antenat
cultur
risk
factor
analysi
sensit
idistrepb
assay
superior
advantag
applic
decreas
turnaround
time
rel
cultur
intrapartum
set
addit
data
regard
sensit
specifi
citi
molecular
test
gb
detect
shown
tabl
use
molecular
method
diagnosi
sepsi
challeng
endeavor
one
fdaapprov
test
avail
identifi
cation
potenti
pathogen
directli
blood
obtain
septic
patient
test
limit
candidemia
gold
standard
remain
autom
blood
cultur
refer
method
may
diffi
cult
match
owe
larg
amount
blood
cultur
typic
ml
nonetheless
research
use
product
avail
direct
test
blood
roch
molecular
system
septifast
branchburg
nj
use
multiplex
realtim
pcr
melt
curv
analysi
molzym
sepsitest
bremen
germani
use
multiplex
pcr
follow
sequenc
sirslab
vyoo
jena
germani
use
multiplex
pcr
follow
gel
electrophoresi
product
vari
organ
resist
determin
detect
well
analyt
perform
characterist
gener
product
suffer
lack
sensit
specifi
citi
well
requir
addit
optim
routin
clinic
use
possibl
shortcom
naabas
diagnosi
sepsi
includ
inconclus
clinic
signifi
canc
detect
pathogen
dna
blood
stream
inabl
obtain
full
antimicrobi
suscept
result
howev
blood
cultur
imperfect
refer
method
suffer
number
limit
includ
prolong
time
pathogen
identifi
cation
effect
variabl
blood
volum
lack
growth
fastidi
pathogen
presenc
prior
antimicrobi
therapi
one
limit
address
molecular
method
time
defi
nitiv
identifi
cation
number
commerci
molecular
test
product
avail
identifi
cation
organ
resist
determin
directli
posit
blood
cultur
bottl
approach
take
advantag
cultur
amplifi
cation
bacteria
blood
ad
molecular
method
lessen
time
identifi
cation
fdaclear
test
use
directli
posit
blood
cultur
bottl
includ
advandx
pnafish
woburn
cepheid
sunnyval
ca
biofi
filmarray
bcid
salt
lake
citi
ut
nanospher
bcgp
bcgn
panel
northbrook
il
molecular
target
product
list
tabl
use
malditof
ms
direct
pathogen
detect
directli
posit
blood
cultur
also
investig
recent
data
show
identifi
cation
rate
sensit
specifi
citi
calcul
use
cultur
gold
standard
vari
depend
whether
use
antepartum
intrapartum
screen
cite
refer
packag
insert
data
indic
asterisk
approxim
reduc
time
identifi
cation
day
sever
studi
demonstr
costeffect
util
rapid
detect
organ
posit
blood
cultur
bottl
puls
fi
eld
gel
electrophoresi
pfge
gold
standard
molecular
epidemiolog
studi
major
organ
brief
bacteri
cell
immobil
agaros
subject
proteolyt
degrad
follow
restrict
endonucleas
digest
result
genom
fragment
separ
pfge
allow
better
resolut
high
molecular
weight
product
pfge
critic
tool
infect
control
public
health
specialti
proven
reproduc
method
show
strain
related
identifi
outbreak
common
approach
molecular
epidemiolog
includ
amplifi
ed
fragment
length
polymorph
aflp
analysi
multi
locu
sequenc
type
mlst
aflp
analysi
base
theori
pfge
differ
dna
sequenc
identifi
ed
differ
restrict
endonucleas
pattern
major
differ
aflp
analysi
pfge
pfge
look
entir
genom
organ
aflp
analysi
emphas
region
genom
known
high
rate
polymorph
mlst
analysi
done
amplifi
sequenc
small
set
known
housekeep
gene
usual
standard
rate
genet
variabl
laborintens
often
expens
approach
molecular
epidemiolog
disadvantag
although
pfge
high
discriminatori
power
reproduc
even
amongst
member
laboratori
variabl
make
longitudin
comparison
diffi
cult
often
requir
strain
run
repeatedli
andor
implement
standard
strain
normal
band
pattern
although
mlst
analysi
reproduc
lack
discriminatori
power
genom
wide
approach
aflp
analysi
pfge
offer
aflp
analysi
tri
combin
discriminatori
power
pfge
reproduc
mlst
analysi
success
approach
applic
organ
malditof
ms
repres
promis
develop
fi
eld
molecular
epidemiolog
provid
rel
fast
easi
method
compar
strain
related
minim
handson
time
malditof
ms
advantag
interrog
entir
proteom
microorgan
although
protein
size
rang
analyz
typic
kda
research
look
abil
malditof
ms
distinguish
bacteri
subspeci
organ
salmonella
studi
perform
compar
abil
malditof
ms
system
directli
pfge
assess
abil
determin
absolut
strain
related
malditof
ms
use
identifi
clonal
popul
mrsa
success
accuraci
debat
remain
seen
howev
level
resolut
malditof
ms
fi
ngerprint
enough
allow
technolog
replac
pfge
epidemiolog
investig
microorgan
advanc
molecular
biolog
last
year
made
astound
impact
clinic
laboratori
test
infecti
diseas
notabl
tb
confi
rmed
h
oppos
week
sexual
transmit
infect
caus
c
trachomati
n
gonorrhoea
rapidli
accur
identifi
ed
improv
treatment
prevent
transmiss
organ
import
infect
control
implic
b
pertussi
mrsa
vre
quickli
identifi
ed
lead
appropri
therapi
andor
precaut
applic
molecular
technolog
clinic
microbiolog
endless
disadvantag
also
abound
molecular
infecti
diseas
laboratori
establish
consider
cost
expertis
still
learn
mani
naa
test
result
mean
term
infecti
etiolog
clinic
signifi
canc
mere
presenc
microorgan
dna
convinc
evid
diseas
causat
addit
clinic
scientifi
c
evid
may
need
valid
clinic
relev
molecularbas
result
though
still
much
learn
appropri
applic
interpret
molecular
infecti
diseas
test
numer
excit
opportun
horizon
use
realtim
pcr
test
clinic
laboratori
revolution
diagnost
microbiolog
expand
capac
multiplex
technolog
allow
simultan
detect
analyt
hour
biofir
diagnost
perhap
technolog
greatest
impact
clinic
microbiolog
use
malditof
ms
identifi
cation
organ
also
potenti
resist
profi
le
strain
type
lastli
nextgener
sequenc
becom
afford
access
clinic
laboratori
clinic
investig
abl
ask
question
pathogenesi
microbiom
chang
real
time
never
clinic
microbiolog
chang
rapid
pace
current
experienc
must
rememb
power
molecular
technolog
coupl
wellcontrol
clinic
relev
diagnost
approach
greatest
impact
patient
care
